Dr. Ajay Kumar Shrivastava has 30+ of experience covering API (Non Sterile & Sterile) Production in the Pharmaceutical sector. He is a keen administrator with recognized proficiency in managing complete production operations entailing production, quality, safety, maintenance, project management for various active pharmaceuticals.
He is skilled in respect to process optimization & process control, standardizing production norms & Good Manufacture Practice. He ensures compliance of various quality measures such as cGMP, by maintenance of appropriate Quality Management and Systems. Ajay has demonstrated analytical, problem solving and organizational abilities coupled with strong communication and relationship management skills. He is building teams and motivating them for achieving their targets.

Dr. Ajay Shrivastava has worked with Indian reputed pharmaceuticals manufacturers, such as Lupin Laboratories Limited, Aurobindo Pharmaceuticals Limited, Macleods Pharmaceuticals Limited, Nectar Lifesciences Limited and Sun Pharmaceuticals Industried Ltd.

During his professional career, he has had a wide exposure to the different regulatory audits such as USFDA, European GMP, PMDA-Japan , WHO-GENEVA, ANVISA-Brazil, MHRA, TGA, and many more.

Dr. Shrivastava's educational background encompasses Biology (B.Sc. from Barkat Ullah University, Bhopal, M.P- India), Applied Chemistry (M.Sc. from Barkat Ullah University, Bhopal, M.P-India), as well as Operation (MBA from Indian school of Business Management and Administration. Ahmedabad).

The Pop in My Job:

My passion lies in people and behavioral understanding so that he can lead and drive my teams. I am ethically committed to Quality and strict no-no for shortcuts. As a team player, I am always leveraging my networking skills to maintain excellent relationships with team and proactively resolve issues and find most beneficial ways of decision making, analyzing & problem solving.

CTX Lifesciences, a vertically integrated API and intermediate manufacturing company was established in the year of 2004 in Surat, India as a part of a privately held group worth US$ 600 million( Colourtex Industries Pvt Ltd) . With 1000 KL of total reactor volume capacity spread across five manufacturing blocks, CTX has access to its own infrastructure viz water reservoir, land fill site, effluent treatment plant and incinerators. Facility spread across 32 acres is USFDA compliant, EU GMP certified, WHO GMP certified and has received accreditations from several international drug authorities. Today, CTX supports the Global Pharmaceutical Industry with supply of its APIs across 70 nations. Moreover Regulatory markets are well catered with 14 assessed USDMFs and 13 approved CEPs.